

Ann W Morgan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7712240/publications.pdf>

Version: 2024-02-01

166
papers

10,147
citations

38720

50
h-index

36008

97
g-index

177
all docs

177
docs citations

177
times ranked

14414
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. <i>Nature Genetics</i> , 2010, 42, 508-514.	9.4	1,132
2	Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. <i>Nature Genetics</i> , 2011, 43, 761-767.	9.4	778
3	Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. <i>Nature</i> , 2010, 464, 713-720.	13.7	737
4	Rheumatoid arthritis association at 6q23. <i>Nature Genetics</i> , 2007, 39, 1431-1433.	9.4	361
5	Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. <i>Nature Genetics</i> , 2009, 41, 1313-1318.	9.4	306
6	The Requirement for DNAM-1, NKG2D, and NKp46 in the Natural Killer Cell-Mediated Killing of Myeloma Cells. <i>Cancer Research</i> , 2007, 67, 8444-8449.	0.4	284
7	Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or <i>PTPN22</i> susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 69-74.	0.5	240
8	Copy number of <i>FCGR3B</i> which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake. <i>Journal of Experimental Medicine</i> , 2008, 205, 1573-1582.	4.2	213
9	Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1202-1210.	0.5	166
10	Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. <i>Blood</i> , 2002, 100, 4550-4556.	0.6	152
11	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. <i>Nature Communications</i> , 2015, 6, 6046.	5.8	149
12	Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. <i>PLoS Genetics</i> , 2013, 9, e1003394.	1.5	146
13	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	2.6	144
14	Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. <i>Nature Genetics</i> , 2008, 40, 1156-1159.	9.4	143
15	Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. <i>Arthritis and Rheumatism</i> , 2011, 63, 645-653.	6.7	143
16	Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 75-85.	0.5	139
17	Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility. <i>Human Molecular Genetics</i> , 2008, 17, 2274-2279.	1.4	131
18	Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 463-468.	0.5	130

#	ARTICLE	IF	CITATIONS
19	Association of HLA-DRB1 Haplotypes With Rheumatoid Arthritis Severity, Mortality, and Treatment Response. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1645.	3.8	119
20	<i>In situ</i> macromolecular crystallography using microbeams. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2012, 68, 592-600.	2.5	113
21	Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. <i>Human Molecular Genetics</i> , 2008, 17, 3532-3538.	1.4	111
22	Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study. <i>PLoS Medicine</i> , 2020, 17, e1003432.	3.9	111
23	Fc γ 3 receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups. <i>Arthritis and Rheumatism</i> , 2000, 43, 2328-2334.	6.7	103
24	Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1641-1644.	0.5	103
25	Rheumatoid arthritis risk allele <i>PTPRC</i> is also associated with response to anti-tumor necrosis factor \pm therapy. <i>Arthritis and Rheumatism</i> , 2010, 62, 1849-1861.	6.7	95
26	Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. <i>Human Molecular Genetics</i> , 2009, 18, 2693-2699.	1.4	93
27	Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease. <i>Arthritis Research and Therapy</i> , 2010, 12, R175.	1.6	92
28	Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. <i>Rheumatology</i> , 2015, 54, 494-499.	0.9	90
29	Clinical Utility of Random Anti-Tumor Necrosis Factor Drug Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 2011-2019.	2.9	90
30	Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1029-1035.	0.5	89
31	Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population. <i>Arthritis and Rheumatism</i> , 2009, 60, 2565-2576.	6.7	86
32	Outrunning free radicals in room-temperature macromolecular crystallography. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2012, 68, 810-818.	2.5	83
33	Standardized protocols for differentiation of THP-1 cells to macrophages with distinct M(IFN γ +LPS), M(IL-4) and M(IL-10) phenotypes. <i>Journal of Immunological Methods</i> , 2020, 478, 112721.	0.6	81
34	Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. <i>Human Molecular Genetics</i> , 2009, 18, 2518-2522.	1.4	78
35	Informed Conditioning on Clinical Covariates Increases Power in Case-Control Association Studies. <i>PLoS Genetics</i> , 2012, 8, e1003032.	1.5	78
36	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	2.6	78

#	ARTICLE	IF	CITATIONS
37	A Multicenter, Randomized, Placebo-Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1437-1449.	2.9	77
38	Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. <i>Arthritis Research</i> , 2005, 7, R80.	2.0	75
39	Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF- κ B signalling pathways. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1315-1320.	0.5	74
40	PADI4 genotype is not associated with rheumatoid arthritis in a large UK Caucasian population. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 666-670.	0.5	73
41	Impact of Psychological Factors on Subjective Disease Activity Assessments in Patients With Severe Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 861-868.	1.5	71
42	Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1387-1393.	0.5	69
43	Evidence to support <i>IL-13</i> as a risk locus for psoriatic arthritis but not psoriasis vulgaris. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1016-1019.	0.5	68
44	Replication of association of the <i>PTPRC</i> gene with response to anti-tumor necrosis factor therapy in a large UK cohort. <i>Arthritis and Rheumatism</i> , 2012, 64, 665-670.	6.7	65
45	Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 143-148.	0.5	65
46	Association of CD40 with rheumatoid arthritis confirmed in a large UK case-control study. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 813-816.	0.5	62
47	Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1353-1360.	2.9	59
48	Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1054-1057.	0.5	55
49	Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 98-103.	0.5	55
50	Predicting the Risk of Rheumatoid Arthritis and Its Age of Onset through Modelling Genetic Risk Variants with Smoking. <i>PLoS Genetics</i> , 2013, 9, e1003808.	1.5	55
51	Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell Arteritis. <i>Medicine (United States)</i> , 2016, 95, e2368.	0.4	55
52	Incidence of infections associated with oral glucocorticoid dose in people diagnosed with polymyalgia rheumatica or giant cell arteritis: a cohort study in England. <i>Cmaj</i> , 2019, 191, E680-E688.	0.9	53
53	Identification of the <i>PTPN22</i> functional variant R620W as susceptibility genetic factor for giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1882-1886.	0.5	51
54	A spectrum of susceptibility to rheumatoid arthritis within HLA-DRB1: stratification by autoantibody status in a large UK population. <i>Genes and Immunity</i> , 2012, 13, 120-128.	2.2	50

#	ARTICLE	IF	CITATIONS
55	Diagnosing late onset rheumatoid arthritis, polymyalgia rheumatica, and temporal arteritis in patients presenting with polymyalgic symptoms. A prospective longterm evaluation. <i>Journal of Rheumatology</i> , 2005, 32, 1043-6.	1.0	50
56	High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 208-213.	0.5	49
57	Fc γ RIIIa Expression on Monocytes in Rheumatoid Arthritis: Role in Immune-Complex Stimulated TNF Production and Non-Response to Methotrexate Therapy. <i>PLoS ONE</i> , 2012, 7, e28918.	1.1	49
58	Dose Dependency of Iatrogenic Glucocorticoid Excess and Adrenal Insufficiency and Mortality: A Cohort Study in England. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3757-3767.	1.8	48
59	Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis. <i>Arthritis Research and Therapy</i> , 2006, 8, R109.	1.6	47
60	Asthma and airways collapse in two heritable disorders of connective tissue. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1369-1373.	0.5	47
61	Fc γ RIIIa-158V and rheumatoid arthritis: a confirmation study. <i>British Journal of Rheumatology</i> , 2003, 42, 528-533.	2.5	46
62	Brief Report: Identification of <i>BACH2</i> and <i>RAD51B</i> as Rheumatoid Arthritis Susceptibility Loci in a Meta-Analysis of Genome-Wide Data. <i>Arthritis and Rheumatism</i> , 2013, 65, 3058-3062.	6.7	43
63	Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 1364-1371.	0.9	43
64	Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: a population-based cohort study. <i>Cmaj</i> , 2020, 192, E295-E301.	0.9	43
65	Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients. <i>Pharmacogenomics Journal</i> , 2018, 18, 528-538.	0.9	42
66	Novel Rheumatoid Arthritis Susceptibility Locus at 22q12 Identified in an Extended UK Genome-Wide Association Study. <i>Arthritis and Rheumatology</i> , 2014, 66, 24-30.	2.9	41
67	Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2018, 18, 657-664.	0.9	41
68	The shared epitope hypothesis in rheumatoid arthritis: Evaluation of alternative classification criteria in a large UK Caucasian cohort. <i>Arthritis and Rheumatism</i> , 2008, 58, 1275-1283.	6.7	40
69	Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation. <i>Arthritis Research and Therapy</i> , 2015, 17, 195.	1.6	40
70	Analysis of Fc γ receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B. <i>Arthritis Research and Therapy</i> , 2006, 8, R5.	1.6	39
71	Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1350-1354.	0.5	39
72	Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 1400-1409.	0.9	39

#	ARTICLE	IF	CITATIONS
73	Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients. <i>Clinical and Experimental Immunology</i> , 2012, 170, 36-46.	1.1	38
74	Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort. <i>Arthritis Research and Therapy</i> , 2010, 12, R57.	1.6	37
75	Variants in linkage disequilibrium with the late cornified envelope gene cluster deletion are associated with susceptibility to psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2199-2203.	0.5	36
76	Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoantibody positive rheumatoid arthritis. <i>Human Mutation</i> , 2012, 33, 741-749.	1.1	36
77	Affimer proteins inhibit immune complex binding to Fcγ3RIIIa with high specificity through competitive and allosteric modes of action. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E72-E81.	3.3	36
78	Non-communicable disease, sociodemographic factors, and risk of death from infection: a UK Biobank observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1184-1191.	4.6	36
79	Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 319-323.	0.7	35
80	Cardiovascular risk and rheumatoid arthritis—the next step: differentiating true soluble biomarkers of cardiovascular risk from surrogate measures of inflammation. <i>Rheumatology</i> , 2011, 50, 1944-1954.	0.9	35
81	Confirmation of association of the REL locus with rheumatoid arthritis susceptibility in the UK population. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1572-1573.	0.5	32
82	Human immunodeficiency virus associated spondyloarthropathy: pathogenic insights based on imaging findings and response to highly active antiretroviral treatment. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 696-698.	0.5	31
83	Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factors. <i>Rheumatology</i> , 2011, 50, 2014-2022.	0.9	31
84	Cross-phenotype analysis of ImmunoChip data identifies <i>KDM4C</i> as a relevant locus for the development of systemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 589-595.	0.5	27
85	Persistently moderate DAS-28 is not benign: loss of function occurs in early RA despite step-up DMARD therapy. <i>Rheumatology</i> , 2010, 49, 1894-1899.	0.9	25
86	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for <i>CD40</i> and <i>CD39</i> . <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1055-1061.	0.5	25
87	Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes. <i>Rheumatology</i> , 2021, 60, 617-628.	0.9	22
88	Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis—results from the IDEA study. <i>Rheumatology</i> , 2016, 55, 2181-2190.	0.9	21
89	A High-Throughput Amplicon Screen for Somatic UBA1 Variants in Cytopenic and Giant Cell Arteritis Cohorts. <i>Journal of Clinical Immunology</i> , 2022, 42, 947-951.	2.0	21
90	Investigating the viability of genetic screening/testing for RA susceptibility using combinations of five confirmed risk loci. <i>Rheumatology</i> , 2009, 48, 1369-1374.	0.9	20

#	ARTICLE	IF	CITATIONS
91	Relationship between area-level socio-economic deprivation and autoantibody status in patients with rheumatoid arthritis: multicentre cross-sectional study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1640-1645.	0.5	20
92	Allele dose association of the C5orf30rs26232 variant with joint damage in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, n/a-n/a.	6.7	20
93	Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. <i>Arthritis Research and Therapy</i> , 2012, 14, R214.	1.6	18
94	Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. <i>Lancet, The</i> , 2015, 385, S48.	6.3	18
95	The Effect of Endogenous Cushing Syndrome on All-cause and Cause-specific Mortality. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2377-2388.	1.8	18
96	Giant cell arteritis: new concepts, treatments and the unmet need that remains. <i>Rheumatology</i> , 2019, 58, 1123-1125.	0.9	17
97	MTHFR functional genetic variation and methotrexate treatment response in rheumatoid arthritis: a meta-analysis. <i>Pharmacogenomics</i> , 2014, 15, 467-475.	0.6	16
98	Investigation of IL1, VEGF, PPARC and MEFV genes in psoriatic arthritis susceptibility: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 313-314.	0.5	15
99	Metaanalysis of the Association of Smoking and PTPN22 R620W Genotype on Autoantibody Status and Radiological Erosions in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 1048-1053.	1.0	15
100	Prediction of treatment response in rheumatoid arthritis patients using genome-wide SNP data. <i>Genetic Epidemiology</i> , 2018, 42, 754-771.	0.6	15
101	Toward Individualized Prediction of Response to Methotrexate in Early Rheumatoid Arthritis: A Pharmacogenomics-Driven Machine Learning Approach. <i>Arthritis Care and Research</i> , 2022, 74, 879-888.	1.5	15
102	Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels. <i>Rheumatology</i> , 2016, 55, 2050-2055.	0.9	14
103	A re-evaluation of three putative functional single nucleotide polymorphisms in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1373-1375.	0.5	13
104	Evaluating tertiary adrenal insufficiency in rheumatology patients on long-term systemic glucocorticoid treatment. <i>Clinical Endocrinology</i> , 2021, 94, 361-370.	1.2	13
105	A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2008, 101, 299-306.	0.2	12
106	Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 338-341.	0.7	12
107	Effect of Fatigue, Older Age, Higher Body Mass Index, and Female Sex on Disability in Early Rheumatoid Arthritis in the Treatment-Target Era. <i>Arthritis Care and Research</i> , 2018, 70, 361-368.	1.5	12
108	Oral 11 β -HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trial. <i>European Journal of Endocrinology</i> , 2022, 186, 441-455.	1.9	12

#	ARTICLE	IF	CITATIONS
109	Genetic associations with radiological damage in rheumatoid arthritis: Meta-analysis of seven genome-wide association studies of 2,775 cases. <i>PLoS ONE</i> , 2019, 14, e0223246.	1.1	11
110	Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment. <i>Arthritis Research and Therapy</i> , 2021, 23, 80.	1.6	11
111	The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort. <i>Rheumatology</i> , 2017, 56, kew387.	0.9	10
112	No evidence for association of the KLF12 gene with rheumatoid arthritis in a large UK cohort. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1407-1408.	0.5	9
113	Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2010, 49, 43-47.	0.9	9
114	Rheumatoid arthritis response to treatment across IgG1 allotype " anti-TNF incompatibility: a case-only study. <i>Arthritis Research and Therapy</i> , 2015, 17, 63.	1.6	9
115	Previously reported "SLCO1C1" genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort. <i>Pharmacogenomics</i> , 2016, 17, 715-720.	0.6	9
116	Latent Class Trajectory Modeling of 2-Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease-Modifying Antirheumatic Drugs. <i>Arthritis and Rheumatology</i> , 2020, 72, 1632-1642.	2.9	9
117	Rapid visual recovery following intravenous tocilizumab in glucocorticoid resistant refractory giant cell arteritis. <i>BMJ Case Reports</i> , 2019, 12, e229236.	0.2	8
118	Interplay between demographic, clinical and polygenic risk factors for severe COVID-19. <i>International Journal of Epidemiology</i> , 2022, 51, 1384-1395.	0.9	8
119	Laboratory findings and pathology of psoriatic arthritis. <i>Bailliere's Clinical Rheumatology</i> , 1994, 8, 439-463.	1.0	7
120	Analysis of the insertion/deletion related polymorphism within T cell antigen receptor \hat{A} variable genes in primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2004, 64, 468-470.	0.5	7
121	A methodological framework for AI-assisted diagnosis of active aortitis using radiomic analysis of FDG PET-CT images: Initial analysis. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 3315-3331.	1.4	7
122	Testing the role of vitamin D in response to antitumour necrosis factor \hat{I} therapy in a UK cohort: a Mendelian randomisation approach. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 938-940.	0.5	6
123	Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples. <i>Arthritis Research and Therapy</i> , 2015, 17, 359.	1.6	6
124	Patient-reported Outcomes as Predictors of Change in Disease Activity and Disability in Early Rheumatoid Arthritis: Results from the Yorkshire Early Arthritis Register. <i>Journal of Rheumatology</i> , 2017, 44, 1331-1340.	1.0	6
125	Does the shared epitope genotype influence either the susceptibility to or the phenotype of corneal melting?. <i>Eye</i> , 2001, 15, 492-496.	1.1	5
126	Systemic Inflammation Is Associated With Future Risk of Fatal Infection: An Observational Cohort Study. <i>Journal of Infectious Diseases</i> , 2022, 226, 554-562.	1.9	5

#	ARTICLE	IF	CITATIONS
127	Unique TCR β -subunit variable gene haplotypes in Africans. <i>Immunogenetics</i> , 2002, 53, 884-893.	1.2	4
128	Validity and reliability of the Persian version of Behçet's disease quality-of-life (BD-QoL) questionnaire: a cross-cultural adaptation. <i>Rheumatology International</i> , 2015, 35, 677-684.	1.5	4
129	Association of Fc γ receptor IIIA polymorphism with rheumatoid arthritis: Comment on the article by Morgan et al. <i>Arthritis and Rheumatism</i> , 2002, 46, 556-557.	6.7	3
130	Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. <i>Pharmacogenomics Journal</i> , 2014, 14, 171-175.	0.9	3
131	Emergence of proinflammatory autoreactive T-cell responses in preclinical rheumatoid arthritis. <i>Lancet, The</i> , 2014, 383, S22.	6.3	3
132	Achieving consensus on minimum data items (including core outcome domains) for a longitudinal observational cohort study in rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, kew416.	0.9	3
133	A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility. <i>PLoS ONE</i> , 2018, 13, e0209343.	1.1	3
134	Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 1684-1686.	0.9	3
135	Self-risk assessment for patients with rheumatic disease during the COVID-19 pandemic. <i>Lancet Rheumatology, The</i> , 2020, 2, e386-e387.	2.2	3
136	Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score. <i>Pharmacogenomics</i> , 2020, 21, 1151-1156.	0.6	3
137	Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy. <i>Rheumatology</i> , 2022, 61, 4935-4944.	0.9	3
138	Prediction model for rheumatoid arthritis: modelling 46 genetic risk variants with smoking. <i>Lancet, The</i> , 2013, 381, S97.	6.3	2
139	Curry-assisted diagnosis in the rheumatology clinic. <i>Oxford Medical Case Reports</i> , 2015, 2015, 297-299.	0.2	2
140	Angiogenesis and Giant Cell Arteritis. , 2010, , 383-402.		1
141	P189: A longitudinal study of psychological predictors of response to adalimumab in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, .	0.9	1
142	Fc γ receptors are critical modulators of inflammation within the synovium: Comment on the article by Blom et al. <i>Arthritis and Rheumatism</i> , 2004, 50, 1352-1353.	6.7	0
143	Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. <i>Human Molecular Genetics</i> , 2010, 19, 4544-4544.	1.4	0
144	The contribution of genetic risk factors other than the HLA shared epitope alleles to the genetic variance of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A52.1-A52.	0.5	0

#	ARTICLE	IF	CITATIONS
145	Effect of inadequate adherence on clinical outcomes: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. <i>Lancet, The</i> , 2014, 383, S26.	6.3	0
146	342.â€ŒIs Plasma Viscosity an Acceptable Substitute for Erythrocyte Sedimentation Rate for the Diagnosis of Giant Cell Arteritis?. <i>Rheumatology</i> , 2014, 53, i188-i188.	0.9	0
147	O49.â€ŒPersonalized Genetic Medicine: Amino Acid Positions 11, 71 and 74 in HLA-DRB1 Predict Disease Severity, Mortality and Treatment Response in Rheumatoid Arthritisâ€Œ Multi-Centre Prospective Cohort Studies. <i>Rheumatology</i> , 2015, , .	0.9	0
148	I25â€ŒOverview of Stratified Medicine: What is it and what Examples are there of Successful Application?. <i>Rheumatology</i> , 2016, , .	0.9	0
149	O50â€ŒHigh Frequency of Anti-Drug Antibodies and Correlation of Low Random Drug Levels with Lack of Efficacy in Certolizumab Pegol-Treated Patients with Rheumatoid Arthritis. <i>Rheumatology</i> , 0, , .	0.9	0
150	Neonatal BehÃŒset's disease. <i>Archives of Disease in Childhood</i> , 2017, 102, 1062-1062.	1.0	0
151	O12â€ŒValidity of a2-component imaging-derived disease activity score (2C-DAS28) for improved assessment of synovitis in early rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, .	0.9	0
152	i006â€ŒRheumatologist perspective: management of uveitis and inflammatory eye diseases. <i>Rheumatology</i> , 2018, 57, .	0.9	0
153	O10â€ŒTemporal artery biopsy: audit, scoring and reporting. <i>Rheumatology</i> , 2019, 58, .	0.9	0
154	SAT0062â€Œ...STRATIFIED MEDICINE FOR RHEUMATOID ARTHRITIS: PREDICTING RESPONSE TO BIOLOGIC THERAPY USING IMMUNE CELL SIGNATURES. , 2019, , .		0
155	FRIO017â€Œ...DIFFERENTIAL METHYLATION AS A PREDICTOR OF TOCILIZUMAB RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
156	SAT0009â€Œ...THE EFFECT OF FCGR3A POLYMORPHISM ON THE INITIAL DEPTH OF B-CELL DEPLETION BY RITUXIMAB, FUNCTIONAL NK-CELL MEDIATED KILLING AND CLINICAL RESPONSE IN SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
157	Title is missing!. , 2020, 17, e1003432.		0
158	Title is missing!. , 2020, 17, e1003432.		0
159	Title is missing!. , 2020, 17, e1003432.		0
160	Title is missing!. , 2020, 17, e1003432.		0
161	OA13â€ŒComprehensive genetic and functional analyses of Fc gamma receptors explain response to rituximab therapy for autoimmune rheumatic diseases. <i>Rheumatology</i> , 2022, 61, .	0.9	0
162	P200â€ŒCombining protein quantitative trait and genetic risk score analysis to identify biomarkers of treatment response to TNFi in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, .	0.9	0

#	ARTICLE	IF	CITATIONS
163	OA24 Predicting drug immunogenicity to tumour necrosis factor inhibitors in patients with rheumatoid arthritis. Rheumatology, 2022, 61, .	0.9	0
164	OA15 Drivers of change in four and two component disease activity scores after etanercept treatment, in a multi-centre cohort of patients with established rheumatoid arthritis. Rheumatology, 2022, 61, .	0.9	0
165	OA26 Erythrocyte mean corpuscular volume as a surrogate marker for methotrexate polyglutamation during early treatment in rheumatoid arthritis. Rheumatology, 2022, 61, .	0.9	0
166	OA16 Therapeutic certolizumab pegol drug levels to achieve good EULAR response in patients with rheumatoid arthritis: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS) cohort. Rheumatology, 2022, 61, .	0.9	0